Cited by 511Cancer Immunotherapy and BiomarkersChemotherapy-induced cardiotoxicity and mitigationCardiac tumors and thrombi

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Open access

Heinzerling, Lucie, Ott, Patrick A., Hodi, F. Stephen, Husain, Aliya N., Tajmir-Riahi, Azadeh, Tawbi, Hussein, Pauschinger, Matthias, Gajewski, Thomas F., Lipson, Evan J., Luke, Jason J.·2016·Journal for ImmunoTherapy of Cancer

DOI 10.1186/s40425-016-0152-yPMC PMC4986340

Open this paper in CoChat — free account Open PDF

Abstract

Immune-checkpoint blocking antibodies have demonstrated objective antitumor responses in multiple tumor types including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). In melanoma, an increase in overall survival has been demonstrated with anti-CTLA-4 and PD-1 inhibition. However, a plethora of immune-mediated adverse events has been reported with these agents. Immune-mediated cardiotoxicity induced by checkpoint inhibitors has been reported in single cases with variable presentation, including myocarditis and pericarditis. Among six clinical cancer centers with substantial experience in the administration of immune-checkpoint blocking antibodies, eight cases of immune-related cardiotoxicity after ipilimumab and/or nivolumab/pembrolizumab were identified. Diagnostic findings, treatment and follow-up are reported. A large variety of cardiotoxic events with manifestations such as heart failure, cardiomyopathy, heart block, myocardial fibrosis and myocarditis was documented. This is the largest case series to date describing cardiotoxicity of immune-checkpoint blocking antibodies. Awareness, monitoring of patients with pre-existing cardiac disorders and prompt evaluation by the treatment team is essential. Treatment including application of steroids is critical for patient safety.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/s40425-016-0152-y

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1 Histologic presentation of case 1. Endomyocardial biopsy shows interstitial fibrosis with some interstitial lymphocytes. Signs of hypertrophy are detectableCC BY · PubMed Central

Fig. 2 Histologic presentation of case 5. a H&E stain of the endomyocardial biopsy shows patchy lymphohistiocytic infiltrates associated with myocyte damage, diagnostic for lymphocytic myocarditis. b IHC stain for CD3 highlights in brown T cells within the inflammatory infiltrate (c) IHC stain for CD8 highlights in brown T cells within the inflammatory infiltrate (d) IHC stain for CD68 shows many histiocytes/macrophages within the myocardial inflammationCC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citation
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Self-citation
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citation
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868

Show all 37 references

Research works printed but not linked: 1

Larkin J, D’Angelo S, Sosman JA, Lebbe C, Brady B, Neyns B, et al. Efficacy and safety of nivolumab (NIVO) monotherapy in the treatment of advanced mucosal melanoma. Pigment Cell Melanoma Res. 2016;28:789.

Sorted by citations

Items 301–400 of 510

Chemotherapy in focus: A meta-analysis confronts immunotherapy in the treatment of advanced melanoma
Gonçalves, V. D. M. D. A., Filho, M. F. D. A. C., Zaleski, T., Boas, R. R. V., Ribeiro, E. R., Vaz, R. S., & Cavassin, F. B. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103304 · Cited by 11
Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block
Khan, A., Riaz, S., & Carhart, R. L. (2020) · Case Reports in Cardiology · doi:10.1155/2020/8428210 · Cited by 11
Cellular Alterations in Immune Checkpoint Inhibitor Therapy-Related Cardiac Dysfunction
Michel, L., Ferdinandy, P., & Rassaf, T. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00652-2 · Cited by 10
Insight of immune checkpoint inhibitor related myocarditis
Pi, J.-K., Chen, X.-T., Zhang, Y., Chen, X.-M., Wang, Y.-C., Xu, J., Zhou, J.-H., Yu, S.-S., & Wu, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113559 · Cited by 11
Electrophysiologic Complications in Cancer Patients
Lee, D. H., Chandrasekhar, S. A., & Fradley, M. G. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-4-282 · Cited by 10
Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada
Dai, W. F., Beca, J. M., Croxford, R., Isaranuwatchai, W., Menjak, I. B., Petrella, T. M., Mittmann, N., Earle, C. C., Gavura, S., Mercer, R. E., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33357 · Cited by 11
The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
Agmon, I. N., Zadok, O. I. B., & Kornowski, R. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11030865 · Cited by 10
Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances
Dehghani, T., Shahrjerdi, A., Kahrizi, M. S., Soleimani, E., Ravandeh, S., Merza, M. S., Rahnama, N., Ebrahimzadeh, F., & Bakhshesh, M. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154470 · Cited by 10
Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine
Samuel, Y., Babu, A., Karagkouni, F., Ismail, A., Choi, S., & Boussios, S. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45100526 · Cited by 10
Nivolumab in squamous cell carcinoma of the head and neck
Specenier, P. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1456337 · Cited by 10
Cardiotoxicity of immune checkpoint inhibitors: An updated review
Behravesh, S., Shomali, N., Danbaran, G. R., Aslani, S., Hemmatzadeh, M., Hosseinzadeh, R., Shabgah, A. G., & Mohammadi, H. (2020) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.2081 · Cited by 11
A perspective on the impact of radiation therapy on the immune rheostat
McBride, W. H., Ganapathy, E., Lee, M.-H., Nesseler, J. P., Nguyen, C., & Schaue, D. (2017) · British Journal of Radiology · doi:10.1259/bjr.20170272 · Cited by 10
Standing up to the cardiometabolic consequences of hematological cancers
Howden, E. J., Gerche, A. L., Arthur, J. F., McMullen, J. R., Jennings, G., Dunstan, D. W., Owen, N. G., Avery, S., & Kingwell, B. A. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.005 · Cited by 11
Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy
Logotheti, S., Pavlopoulou, A., Rudsari, H. K., Galow, A.-M., Kafalı, Y., Kyrodimos, E., Giotakis, A. Ι., Marquardt, S., Velalopoulou, A. P., Verginadis, I. I., et al. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108670 · Cited by 10
Cardiovascular adverse events and immune-related adverse events associated with PD-1/PD-L1 inhibitors for head and neck squamous cell carcinoma (HNSCC)
Abulizi, A., Yan, G.-P., Xu, Q., Muhetaer, R., Wu, S., Abudukelimu, K., Chen, X., Liu, C., & Li, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-75099-5 · Cited by 9
Characterizing Stroke Clots Using Single‐Cell Sequencing
Renedo, D. B., Barak, T., DeLong, J. H., Acosta, J., Sujijantarat, N., Koo, A. B., Antonios, J. P., Rivier, C. A., Clocchiatti‐Tuozzo, S., Huo, S., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.041738 · Cited by 9
Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels
Scard, C., Nguyen, J., Varey, É., Moustaghfir, I., Khammari, A., & Dréno, B. (2021) · European Journal of Dermatology · doi:10.1684/ejd.2021.4009 · Cited by 9
Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance
Che, X., Qi, X., Xu, Y., Wang, Q., & Wu, G. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6613151 · Cited by 9
Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis
Ni, Y., Lei, J., Huang, W., Wang, J., Guo, H., Lv, F., Kang, S., Lan, K., & Jiang, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1092663 · Cited by 9
Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event
Zarifa, A., Salih, M., Lopez‐Mattei, J., Lee, H. J., Iliescu, C., Hassan, S. A., Palaskas, N. L., Durand, J., Mouhayar, E., Kim, J. D., et al. (2018) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_15_18 · Cited by 9
Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age
Chanal, J., Kramkimel, N., Ratour, C., Aractingi, S., Guégan, S., & Avril, M. (2019) · Dermatology · doi:10.1159/000492467 · Cited by 9
Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database
Cutroneo, P. M., Isgrò, V., Ientile, V., Santarpía, M., Ferlazzo, G., Fontana, A., Carrega, P., Matarangolo, E., Barnaba, S., Spina, E., et al. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14413 · Cited by 10
Monitoring of the Evolution of Immune Checkpoint Inhibitor Myocarditis With Cardiovascular Magnetic Resonance
Satô, T., Nakamori, S., Watanabe, S., Nishikawa, K., Inoue, T., Imanaka‐Yoshida, K., Ishida, M., Sakuma, H., Ito, M., & Dohi, K. (2020) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.010633 · Cited by 9
Cardio-Oncology Preclinical Models: A Comprehensive Review
Bouleftour, W., Méry, B., Rowinski, E., Rivier, C., Daguenet, É., & Magné, N. (2021) · Anticancer Research · doi:10.21873/anticanres.15348 · Cited by 9
Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer
Lecocq, Q., Debie, P., Puttemans, J., Awad, R. M., Beck, L. D., Ertveldt, T., Vlaeminck, Y. D., Goyvaerts, C., Raes, G., Keyaerts, M., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00857-9 · Cited by 9
Prognostic Signatures and Therapeutic Value Based on the Notch Pathway in Renal Clear Cell Carcinoma
Li, Z., Xin, S., Yu, S., Liang, J., & Zhang, X. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/1669664 · Cited by 9
Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma
Liu, Y., Liu, Z., Zeng, X., Bai, C., Chen, L., Lin, S., & Tian, X. (2019) · BMC Cancer · doi:10.1186/s12885-019-6372-z · Cited by 9
Targeted anti-inflammatory therapy is a new insight for reducing cardiovascular events: A review from physiology to the clinic
Soroureddin, Z., Nouri‐Vaskeh, M., Maleki, M., Baghbanzadeh, A., Hajiasgharzadeh, K., Sadeghi, M. T., & Baradaran, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117720 · Cited by 9
Tumor neoantigens derived from RNA editing events show significant clinical relevance in melanoma patients treated with immunotherapy
Lu, Q., Zhou, W., Fan, L., Ding, T., Wang, W., & Zhang, X. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001565 · Cited by 11
Cardiovascular Health Considerations for Primary Care Physicians Treating Breast Cancer Survivors
Kidane, R. D., Ruddy, K. J., Lin, G. R., & Sandhu, N. P. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.08.014 · Cited by 8
The safety of nivolumab for the treatment of metastatic melanoma
O’Reilly, A., & Larkin, J. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1351537 · Cited by 8
Emerging roles of circular RNAs in cancer therapy-induced cardiotoxicity
Cheng, Z., Qin, W., Li, S., Shao, S.-J., & Liu, B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1152436 · Cited by 8
Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects
Paluri, R. K., Pulipati, Y., & Regalla, D. K. R. (2023) · Oncology Reviews · doi:10.3389/or.2023.11456 · Cited by 8
A new perspective in the prevention and treatment of antitumor therapy-related cardiotoxicity: Intestinal microecology
Meng, C., Wang, X., Fan, L., Fan, Y., Yan, Z., Wang, Y., Li, Y., Zhang, J., & Lv, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115588 · Cited by 8
Lymphozytäre Myokarditis unter Nivolumabtherapie bei metastasiertem klarzelligen Nierenzellkarzinom
Sauer, R., Kiewe, P. M., Desole, M., Schüler, M., Theissig, F., Roth, A. J., & Mairinger, T. (2017) · Der Pathologe · doi:10.1007/s00292-017-0349-y · Cited by 8
Noninvasive, longitudinal imaging-based analysis of body adipose tissue and water composition in a melanoma mouse model and in immune checkpoint inhibitor-treated metastatic melanoma patients
Thaiss, W. M., Gatidis, S., Sartorius, T., Machann, J., Peter, A., Eigentler, T., Nikolaou, K., Pichler, B. J., & Kneilling, M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02765-8 · Cited by 8
Autoimmune Myasthenia, Primary Adrenal Insufficiency, and Progressive Hypothyroidism Due to Pembrolizumab and Axitinib Combination Regimen
Figueroa-Perez, N., Kashyap, R., Bal, D., Khan, S. A., & Pattan, V. (2021) · Cureus · doi:10.7759/cureus.16933 · Cited by 8
Immunotherapy-Related Cardiotoxicity Re-Emergence in Non-Small Cell Lung Cancer – A Case Report
Li, Y., Hu, Y., Yang, B., Jin, C., Ren, H. J., Wu, J., Wang, Z., Wei, Y., Yang, L., & Hu, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s333242 · Cited by 8
Multisystem immune-related adverse events due to toripalimab: Two cases-based review
Chen, Y., Chen, Y., Xie, J., Liu, D. J., & Hong, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1036603 · Cited by 8
PD-1 inhibition disrupts collagen homeostasis and aggravates cardiac dysfunction through endothelial-fibroblast crosstalk and EndMT
Zhang, Z., Yan, Z., Yuan, T., Zhao, X., Wang, M., Liu, G., Gan, L., & Qin, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1549487 · Cited by 8
A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis
van der Vegt, S. A., Wang, Y., Polonchuk, L., Wang, K., Waters, S. L., & Baker, R. E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.966180 · Cited by 8
A case of lymphocytic myocarditis in a patient treated with an immune checkpoint inhibitor, a recent class of chemotherapy agents
Duarte, T., Costa, C., Gonçalves, S., Raposo, L., Ferreira, A. M., Albuquerque, C., Vau, N., & Caria, R. (2022) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.03.013 · Cited by 7
Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials
Jin, C., Jia, Q., Wang, Q., Pu, C., & Tan, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1158690 · Cited by 7
Immune Checkpoint Inhibitor-Associated Myocarditis: A Literature Review
Gul, R., Shehryar, M., Mahboob, A., Kareem, H. K., Inayat, A., Safi, D., & Kamran, A. S. (2024) · Cureus · doi:10.7759/cureus.52952 · Cited by 7
PD-1/PDL1 Blockade Exacerbates Pancreatic Damage and Immune Response in a Mouse Model of Acute Pancreatitis
Xie, T., Wang, N., Yao, G., Xu, S., Wang, D., Liu, X., Hu, L., Lu, G., Shi, R., & Ding, Y. (2021) · Inflammation · doi:10.1007/s10753-021-01430-1 · Cited by 7
Steroid-Refractory Autoimmune Myocarditis after Pembrolizumab Therapy: Failure of Equine Anti-Thymocyte Globulin to Prevent Heart Failure.
Baclig, N. V., Ngo, C. P., Yeh, A. C., Chung, S. H., Cheng, A., Grim, J., Graf, S. A., & Yang, K. (2019) · PubMed · Cited by 7
Nivolumab‐induced fatal myocarditis: A case report
Bharathidasan, K., Abdelnabi, M. H., Abdelmalek, J., Sekhon, J., Butler, W., Quirch, M., & Sosa, E. A. (2023) · Clinical Case Reports · doi:10.1002/ccr3.7306 · Cited by 6
Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy
Pan, H., Liu, P., Kroemer, G., & Kepp, O. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.06.001 · Cited by 7
A review of chemotherapeutic drugs-induced arrhythmia and potential intervention with traditional Chinese medicines
Li, W., Cheng, X., Zhu, G., Hu, Y. C., Wang, Y., Niu, Y., Li, H., Aierken, A., Li, J., Ling, F., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1340855 · Cited by 7
Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1
Brigida, M., Perricelli, A., Sposato, F., Spadafora, M. G., Pomillo, A., & Milito, S. (2020) · Reviews on Recent Clinical Trials · doi:10.2174/1574887115666200622161418 · Cited by 7
Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review
Kazama, S., Morimoto, R., Kimura, Y., Shibata, N., Ozaki, R., Araki, T., Mizutani, T., Oishi, H., Arao, Y., Kuwayama, T., et al. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00112-z · Cited by 7
Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA DICTrankPreprint
Seal, S., Spjuth, O., Hosseini-Gerami, L., García-Ortegón, M., Singh, S., Bender, A., & Carpenter, A. E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.15.562398 · Cited by 7
A systematic review of cardiovascular toxicities induced by cancer immune therapies: Underlying mechanisms, clinical manifestations and therapeutic approaches
Liu, L., Yao, W., Wang, M., Wang, B., Kong, F., Fan, Z., & Fan, G. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.10.004 · Cited by 6
Late-Onset Myocarditis Following Immune Checkpoint Inhibitors Therapy: A Case Series with Literature Review
Muğlu, H., Sünger, E., Köylü, B., Tunalı, D., Erol, C., Selçukbırıcık, F., Bilici, A. E., & Ölmez, Ö. F. (2025) · Medicina · doi:10.3390/medicina61020302 · Cited by 6
Multiorgan Failure From Nivolumab and Ipilimumab: A Case Report and Literature Review
Brazel, D., Lee, S., Mahadevan, A., Warnecke, B., & Parajuli, R. (2023) · Cureus · doi:10.7759/cureus.41781 · Cited by 6
Risk factors and outcomes of pericardial effusion in cancer patients receiving PD-1 inhibitors
Tang, M., Dang, P., Liu, T., Yang, K., Wang, Y., Tse, G., Liu, H., Liu, Y., Chan, J. S. K., Liu, C., et al. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132029 · Cited by 6
Early detection of myocarditis caused by immune checkpoint inhibitor therapy with nivolumab and ipilimumab for advanced recurrent renal cell carcinoma
Todo, M., Gatate, Y., Nakano, S., Kaneko, G., Hagiwara, M., Takahashi, T., Umezawa, Y., Ueda, G., Ishikawa, S., Makino, Y., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-03945-0 · Cited by 6
Clinical and Advanced MRI Techniques for Detection of Checkpoint Inhibitor Associated Myocarditis
Arbune, A., Soufer, A., & Baldassarre, L. A. (2020) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-019-9521-5 · Cited by 6
Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review
Gao, L., Li, X., Guo, Z., Tang, L., Peng, J., & Liu, B. (2022) · Medicine · doi:10.1097/md.0000000000032240 · Cited by 6
Antitumour Drug Induced Cardiovascular Toxicity and Current Tumour Treatment Methods
Gumerova, K. S., Сахаутдинова, Г. М., & Polyakova, I. (2020) · Creative Surgery and Oncology · doi:10.24060/2076-3093-2019-9-4-285-292 · Cited by 6
Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity
Zarifa, A., Lopez‐Mattei, J., Palaskas, N. L., Iliescu, C., Durand, J., & Kim, P. Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-79308-1_15 · Cited by 6
Immunotherapy of solid tumors: how safely treat the patients
Domagala-Kulawik, J. J., Leszek, P., Owczarek, W. D., Rawa, T., Stelmachowska‐Banaś, M., & Rutkowski, P. L. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15314 · Cited by 6
Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice
Parthymos, I., Liamis, G. L., Dounousi, E. C., Pentheroudakis, G. E., Mauri, D., Zarkavelis, G., & Florentin, M. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.102979 · Cited by 6
Unmasking the Rare but Lethal Cardiac Complications of Immune Checkpoint Inhibitor Therapy: A Review of Mechanisms, Risk Factors, and Management Strategies
Chehade, L., Abbas, N., Dagher, K., Mourad, M., Amhez, G., Moumneh, M. B., Kreidieh, L., Kreidieh, F., Pereira, M. M. A. M., & Shamseddine, A. I. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01329-1 · Cited by 5
Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making
Sun, D., Xu, M., Pan, C., Tang, H., Wang, P., Wu, D., & Luo, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.972972 · Cited by 5
Chronic Anthracycline-related Myocarditis Presenting as Diffuse Myocardial Calcification
Pejic, M., Shifman, M., Rose, T. A., & Jeong, D. K. (2019) · Journal of Clinical Imaging Science · doi:10.25259/jcis_113_2019 · Cited by 5
What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications
Frayberg, M., Yung, A., Zubiri, L., Zlotoff, D. A., & Reynolds, K. L. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00844-1 · Cited by 5
Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma
Savarapu, P. K., Abdelazeem, B., Isa, S. O., Kesari, K., & Kunadi, A. R. (2021) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2021.1965708 · Cited by 6
Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report
Ye, Y., Li, Y., Zhang, S., & Han, G. (2022) · Journal of International Medical Research · doi:10.1177/03000605221133259 · Cited by 5
Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity
Zatarain‐Nicolás, E., Martín, P., Márquez‐Rodas, I., Virizuela, J. A., Martín‐Garcia, A., Mitroi, C. D., Cosín-Sales, J., Barrios, V., Sánchez‐Cabo, F., Ibáñez, B., et al. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03217-2 · Cited by 5
Prediction of Cardiac Arrhythmias in Cancer Patients Treated with Immune Checkpoint Inhibitors Using Electrocardiogram
Coşkun, A., Coşkun, E. Ç., Şahin, A. B., Levent, F., Çoban, E., Koca, F., Sali, S., Demir, Ö. F., Deligönül, A., Tenekecioğlu, E., et al. (2025) · Diagnostics · doi:10.3390/diagnostics15101235 · Cited by 4
Risk of Cardiovascular Disease Death in Older Malignant Melanoma Patients: A Population-Based Study
Miao, J., Wang, Y., Gu, X., Lin, W., Ouyang, Z., Wang, M., Chen, M., Zhao, S., Wang, X., & Su, J. (2022) · Cancers · doi:10.3390/cancers14194783 · Cited by 4
Immune Checkpoints and Their Inhibition in T-Cell Lymphomas
Seňavová, J., Rajmonová, A., Heřman, V., Jura, F., Velasova, A., Hamová, I., Tkachenko, A. S., Kupcová, K., & Havránek, O. (2024) · Folia Biologica · doi:10.14712/fb2024070030123 · Cited by 4
MEK inhibitors combined with programmed cell death-1 blockade immunotherapy for metastatic uveal melanoma: is it warranted?
Zanella, A., Doussot, A., Puzenat, E., Aubin, F., & Nardin, C. (2020) · Melanoma Research · doi:10.1097/cmr.0000000000000677 · Cited by 4
Relationship between cardiac arrhythmias and anticancer therapy
Potievskaya, V. I., Амалиевич, А. А., & Kononova, E. V. (2020) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2020-2417 · Cited by 4
Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE)
Swami, N. S., Hwang, W. L., Guo, J. A., Hoffman, H. I., Abramowitz, M. C., El-Bakouny, Z., Beltran, H., Chipidza, F., Choueiri, T. K., Pra, A. D., et al. (2021) · Cancer Genetics · doi:10.1016/j.cancergen.2021.08.004 · Cited by 4
Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
Kogoniya, L. M., Rusanov, М. О., & Shikina, V. Е. (2022) · Oncohematology · doi:10.17650/1818-8346-2022-17-3-127-136 · Cited by 5
Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies
Scott, S. S., Greenlee, A. N., Schwendeman, E. J., Mohammad, S. J., Naughton, M. T., Matzko, A., Diallo, M., Stein, M., Revan, R., Zaramo, T. Z., et al. (2022) · Springer eBooks · doi:10.1007/978-3-031-08309-9_4 · Cited by 4
Expression of New York esophageal squamous cell carcinoma 1 and its association with Foxp3 and indoleamine‐2,3‐dioxygenase in microenvironment of nonsmall cell lung cancer
Wang, H., Yuan, X., Yu, J., Guan, H., Wu, Z., Ban, D., & Wang, M. (2019) · HLA · doi:10.1111/tan.13547 · Cited by 4
Immune Checkpoint Inhibitor-induced Fatal Myositis in a Patient With Squamous Cell Carcinoma and a History of Thymoma
Lücke, E., Ganzert, C., Vielhaber, S., Haybaeck, J., Jechorek, D., Mawrin, C., & Schreiber, J. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.01.008 · Cited by 4
Expansion of Disease Specific Cardiac Macrophages in Immune Checkpoint Inhibitor MyocarditisPreprint
Ma, P., Liu, J., Qin, J., Lai, L., Heo, G. S., Luehmann, H. P., Sultan, D. H., Bredemeyer, A. L., Bajapa, G., Feng, G., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.28.538426 · Cited by 4
Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment
Shang, C., Wang, H., Chen, J., Cao, S., Sun, Y., Sheng, Z., Chu, T., & Zhao, L. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05466-1 · Cited by 3
Phospholipase C Beta 2 as a Key Regulator of Tumor Progression and Epithelial-Mesenchymal Transition via PI3K/AKT Signaling in Renal Cell Carcinoma
Wang, S., Xie, D., Yue, H., Li, G., Jiang, B., Gao, Y., Zheng, Z., Zheng, X., & Wu, G. (2025) · Biomedicines · doi:10.3390/biomedicines13020304 · Cited by 3
[Clinical Diagnosis and Treatment Recommendations for Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor].
Guo, X., Wang, H., Zhou, J., Duan, L., Li, Y., Si, X., Zhang, L., Fang, L., & Zhang, L. (2019) · PubMed · doi:10.3779/j.issn.1009-3419.2019.10.04 · Cited by 3
Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
España, S., Sun, C., Solé-Blanch, C., Boada, A., Martínez‐Cardús, A., & Manzano, J. L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030823 · Cited by 3
From Bench to Bedside: Translational Approaches to Cardiotoxicity in Breast Cancer, Lung Cancer, and Lymphoma Therapies
Nardone, V., Ruggiero, D., Chini, M. G., Bruno, I., Lauro, G., Terracciano, S., Nebbioso, A., Bifulco, G., Cappabianca, S., & Reginelli, A. (2025) · Cancers · doi:10.3390/cancers17071059 · Cited by 3
Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors
Festino, L., & Ascierto, P. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_33 · Cited by 3
State-of-the-art Review: Interventional Onco-Cardiology
Pushparaji, B., Marmagkiolis, K., Miller, C. K., Aziz, M. K., Balanescu, D. V., Donisan, T., Palaskas, N. L., Kim, P. Y., Lopez‐Mattei, J., Çilingiroğlu, M., et al. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00809-x · Cited by 3
Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine
Lai, T. L., Sklar, M., & Weissmueller, N. T. (2020) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2020.1814403 · Cited by 3
Spätfolgen nach Immuntherapie
Duong, S. L.-L., Zierold, S., Kramer, R., Reincke, M., Kerl-French, K., Boehmerle, W., Pavel, M. E., Weckbach, L. T., French, L. E., Knauß, S., et al. (2021) · Der Onkologe · doi:10.1007/s00761-021-00946-3 · Cited by 3
Self-citation
Late-onset pulmonary and cardiac toxicities in a patient treated with immune checkpoint inhibitor monotherapy
Okauchi, S., Sasatani, Y., Hideyasu, Y., & Satoh, H. (2022) · Klinicka onkologie · doi:10.48095/ccko2022150 · Cited by 4
Cardiotoxicity due to biological cancer therapy
Gabrić, I. D. (2017) · Cardiologia Croatica · doi:10.15836/ccar2017.16 · Cited by 3
Vitiligo: the psychosocial effects.
Mason, P. (1997) · PubMed · Cited by 3
Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management
Eftekhar, S. P., Yazdanpanah, N., & Rezaei, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1979396 · Cited by 3
Radiation-Induced Cardiac Dysfunction
Pedersen, L. N., Khoobchandani, M., Brenneman, R., Mitchell, J. D., & Bergom, C. R. (2022) · Heart Failure Clinics · doi:10.1016/j.hfc.2022.02.012 · Cited by 3
Fulminant Myocarditis After Initial Pembrolizumab Treatment for Squamous Cell Carcinoma of the Lung: an Autopsy Case Report
Ohki, T., Shinoda, A., Shigematsu, Y., Terashima, T., & Hatooka, S. (2020) · Haigan · doi:10.2482/haigan.60.335 · Cited by 3
A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy
Li, S., & Tajiri, K. (2020) · Internal Medicine · doi:10.2169/internalmedicine.5962-20 · Cited by 3
Modern strategies for early diagnosis of cardiotoxicity caused by chemotherapy
Лыкова, А. А., & Khidirova, L. D. (2025) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202528111113 · Cited by 2
Beyond monoclonal antibodies: constraints and the case for alternative PD-1/PD-L1-targeting formats
Porozova, N. O., Petukhova, N. V., Gureev, M., Moiseev, I., Eliseev, I. E., Fedorova, L. V., & Porozov, Y. B. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1729468 · Cited by 3
Coronary Vasospasm and Myopericarditis Presenting as ST-Segment Elevation Myocardial Infarction During Immune Checkpoint Inhibitor Therapy
Ali, M. B., Sherif, A., & Hakemi, E. U. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.107924 · Cited by 2

Authors: Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J.
Affiliations: Universitätsklinikum Erlangen (DE)
Dana-Farber Cancer Institute (US)
University of Chicago (US)
The University of Texas MD Anderson Cancer Center (US)
Paracelsus Medizinische Privatuniversität (DE)
Sidney Kimmel Comprehensive Cancer Center (US)
Corresponding author: Heinzerling, Lucie
ORCID: Heinzerling, Lucie
Ott, Patrick A.
Hodi, F. Stephen
Husain, Aliya N.
Tawbi, Hussein
Pauschinger, Matthias
Gajewski, Thomas F.
Lipson, Evan J.
Luke, Jason J.
Venue: Journal for ImmunoTherapy of Cancer
Publisher: BMJ
Published: 2016-08-16
Volume: 4
Issue: 1
Pages: 50-50
ISSN: 2051-1426 (ISSN-L)
DOI: 10.1186/s40425-016-0152-y
PMC: PMC4986340
OpenAlex: W2478478625
Cited by: 511
References: 37
Citations by year: 2026: 21 · 2025: 29 · 2024: 34 · 2023: 43 · 2022: 50 · 2021: 77 · 2020: 78 · 2019: 64 · 2018: 61 · 2017: 50 · 2016: 2
FWCI: 31.82
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
Locations: Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
Europe PMC (PubMed Central) (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by)
Funders: Melanoma Research Alliance
Celldex Therapeutics
National Institutes of Health
Genentech
National Cancer Institute (K12CA139160)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac tumors and thrombi
Keywords: immune-related cardiotoxicity, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, ipilimumab, nivolumab, pembrolizumab, myocarditis, pericarditis, heart failure, cardiomyopathy, myocardial fibrosis, atrioventricular block, corticosteroid therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks